IL271212A - Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor - Google Patents

Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor

Info

Publication number
IL271212A
IL271212A IL271212A IL27121219A IL271212A IL 271212 A IL271212 A IL 271212A IL 271212 A IL271212 A IL 271212A IL 27121219 A IL27121219 A IL 27121219A IL 271212 A IL271212 A IL 271212A
Authority
IL
Israel
Prior art keywords
administering
methods
diabetic patients
pcsk9 inhibitor
treating hyperlipidemia
Prior art date
Application number
IL271212A
Other languages
Hebrew (he)
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2018/054182 external-priority patent/WO2018225041A1/en
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of IL271212A publication Critical patent/IL271212A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL271212A 2017-06-09 2019-12-05 Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor IL271212A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762517672P 2017-06-09 2017-06-09
US201762532162P 2017-07-13 2017-07-13
EP18305565 2018-05-04
PCT/IB2018/054182 WO2018225041A1 (en) 2017-06-09 2018-06-09 Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor

Publications (1)

Publication Number Publication Date
IL271212A true IL271212A (en) 2020-01-30

Family

ID=62815099

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271212A IL271212A (en) 2017-06-09 2019-12-05 Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor

Country Status (9)

Country Link
EP (1) EP3634469A1 (en)
JP (2) JP2020522544A (en)
KR (1) KR20200026826A (en)
CN (1) CN110913889A (en)
AU (1) AU2018280567A1 (en)
CA (1) CA3066317A1 (en)
IL (1) IL271212A (en)
MX (1) MX2019014831A (en)
TW (2) TW201904608A (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR087305A1 (en) 2011-07-28 2014-03-12 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT
MX2018002000A (en) 2015-08-18 2018-06-19 Regeneron Pharma Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis.
CN113876956B (en) * 2020-07-01 2023-07-04 陈敏 Application of PCSK9 inhibitor in preparation of product for promoting skin pigmentation
CN114525258A (en) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell expressing PCSK9 blocker or derivative thereof and application
CN115992138A (en) * 2021-09-30 2023-04-21 北京安龙生物医药有限公司 Targeting oligonucleotides for treating PCSK 9-related diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (en) * 2008-12-15 2020-08-27 Regeneron Pharma High Affinity Human Antibodies to PCSK9
AU2015289617B2 (en) * 2014-07-16 2021-04-15 Regeneron Pharmaceuticals, Inc. Methods for treating high cardiovascular risk patients with hypercholesterolemia
CA2955294A1 (en) * 2014-07-16 2016-01-21 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
MX2018002000A (en) * 2015-08-18 2018-06-19 Regeneron Pharma Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis.

Also Published As

Publication number Publication date
RU2019144346A3 (en) 2021-10-13
MX2019014831A (en) 2020-02-13
AU2018280567A1 (en) 2020-01-23
CN110913889A (en) 2020-03-24
JP2020522544A (en) 2020-07-30
RU2019144346A (en) 2021-07-09
TW202310872A (en) 2023-03-16
JP2023123842A (en) 2023-09-05
TW201904608A (en) 2019-02-01
CA3066317A1 (en) 2018-12-13
EP3634469A1 (en) 2020-04-15
KR20200026826A (en) 2020-03-11

Similar Documents

Publication Publication Date Title
IL271212A (en) Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
IL244995B (en) Pharmaceutical composition comprising pcsk9 inhibitor for use in treating hyperlipidemia
IL259479B (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
EP3368062A4 (en) Methods for treating craniosynostosis in a patient
MX2017004471A (en) Triazolopyridine compounds and methods for the treatment of cystic fibrosis.
PL3169353T3 (en) Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
PL3371165T3 (en) A btk inhibitor for use in treating cancer
IL261420A (en) Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
EP3313514A4 (en) Positioning device for use in therapeutic treatment
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
EP3862000C0 (en) Medicine for treating chronic cough
HK1252514A1 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
IL227374A0 (en) Guiding means for administering acupuncture and other healing procedures
PL3406258T3 (en) Medicament for use in treating gout
MX2017007245A (en) Methods of treating fibrosis.
EP3391052A4 (en) Methods of preventing or treating hypoglycemia by administering a gpr119 agonist
GB201511595D0 (en) Medical device for treating a vein
IL271456B (en) Pharmaceutical composition comprising pcsk9 inhibitor for use in treating hyperlipidemia
PT3167881T (en) Locally administered ethamsylate as a medicament
UA86338U (en) Method for treating gestational diabetes
GB201712192D0 (en) SmartDepo-(extended-release injections) a promising new drug treatment for addiction
IL250080A0 (en) Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
SG10201911565YA (en) Method for identifying personalized therapeutic strategies for patients affected with a cancer
SG10201400824YA (en) Therapeutic Methods And Compositions For Treating Diabetes Utilizing Diterpenoid Compounds
UA92214U (en) Method for treating diabetic polyneuropathy in patients with diabetes mellitus type 2